The two market leaders are targeting new obesity alternatives in their pipelines with an eye toward a triple threat.

Eli Lilly (NYSE:LLY) experienced a 6% increase in price over the last quarter, coinciding with several major developments.

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth ...

Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved 24% weight reduction at 48 weeks in a ...

Eli Lilly said it needs to expand its global injectable product manufacturing network, which the company said will help to meet growing demand for its diabetes, obesity and future pipeline ...

Eli Lilly is advancing its diabetes and obesity treatment with an oral drug, orforglipron. In an exclusive interaction, CEO ...

ProQR has strategic partnerships with Eli Lilly and the Rett Syndrome Research Trust, enhancing its product pipeline and research funding. What is the current financial status of ProQR?

Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and it's an element you can count on ...

Series B funding secured from investors, including founder Flagship Pioneering and Eli Lilly & CompanyTwo lead programs in ...